Evaluation of Physicochemical Properties, Pharmacokinetics, Biodistribution, Toxicity, and Contrast-Enhanced Cancer MRI of a Cancer-Targeting Contrast Agent, MT218
Conclusion
The preclinical assessments showed that the targeted contrast agent MT218 has high r1 and r2 relaxivities, satisfactory physicochemical properties, pharmacokinetic, and safety profiles and produces effective tumor enhancement in multiple cancer types in rats and mice at reduced doses.
Source: Investigative Radiology - Category: Radiology Tags: Special Issue 2022-Contrast Media Source Type: research
More News: Anaphylactic Shock | Bone Graft | Brain | Brain Cancers | Cancer | Cancer & Oncology | Cardiology | Cardiovascular | Heart | Lung Cancer | MRI Scan | Neurology | Pancreas | Pancreatic Cancer | Prostate Cancer | Radiology | Respiratory Medicine | Toxicology